Published: 6 January 2022
Author(s): Marco Caminati, Veronica Batani, Lucia Guidolin, Giuliana Festi, Gianenrico Senna
Issue: May 2022
Section: Letter to the Editor

Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to Aspergillus fumigatus, mainly characterized by severe asthma symptoms, hyper eosinophilia in blood, lung and airways, elevated serum IgE levels, bronchiectasis, bronchial mucoid impaction and lung fibrosis [1]. As recently remarked, oral corticosteroids (OCS) and antifungal therapy currently represent the gold standard treatment [2]; however, despite their proven efficacy, they may cause severe side effects, especially in the case of prolonged therapy.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.